News for TScan Therapeutics, Inc. (TCRX)

WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. ( TCRX), a clinical-stage biotechnology company focused on the development of T cel

On December 31, 2024, ADAGE CAPITAL PARTNERS GP, L.L.C. (Trades, Portfolio) executed a significant transaction involving TScan Therapeutics Inc (TCRX). The firm

TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia. See why I rate TCRX stock as a buy.

The heavy selling pressure might have exhausted for TScan Therapeutics (TCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Biotech company TScan Therapeutics (TCRX) has announced a plan to sell approximately $30 million in pre-funded warrants. These warrants will allow the purchase

TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027.

TScan Therapeutics (TCRX) announced on Thursday the sale of ~$30M of pre-funded warrants to purchase up to an aggregate of 7.5M voting shares at $4.00 per pre-funded warrant.

**media[500884]**

TScan secures $30 million through warrant sale to Lynx1

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. ( TCRX), a clinical-stage biotechnology company focused on the development of T cel

New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029 WALTHAM, Mass., Dec. 23, 2024 (GLOBE N

**media[487657]**

WALTHAM, Mass., Dec. 05, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. ( TCRX), a clinical-stage biotechnology company focused on the development of T ce

Baker Brothers' 13F portfolio value decreased from $7.97B to $7.83B this quarter. Click here to read more about its fund holdings.

Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role...

Baker Brothers' 13F portfolio value declines but continues to hold significant stakes in biopharmaceutical companies and boasts past successful. Read more here.

WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...

The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.00 A.M. ET)..

The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.00 A.M. ET)..